Loading clinical trials...
Loading clinical trials...
Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants
Conditions
Interventions
DTaP-IPV//PRP~T combined vaccine
DTaP-IPV//PRP~T combined vaccine
Locations
1
Argentina
Córdoba, Córdoba Province, Argentina
Start Date
February 1, 2006
Primary Completion Date
April 1, 2007
Completion Date
September 1, 2007
Last Updated
February 22, 2013
NCT07203755
NCT07112144
NCT06947499
NCT06803524
NCT07149454
NCT06258057
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions